Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday

Immuneering (NASDAQ:IMRX) is set to release its quarterly earnings results before the stock market opens on Friday, March 7th. Analysts predict that the company will report earnings of ($0.47) per share for the quarter.

Immuneering Stock Performance

On Friday, shares of Immuneering opened at $1.67. The company currently has a market capitalization of $51.70 million and a price-to-earnings ratio of -0.85, with a beta of -0.36. Over the past year, Immuneering's stock has seen a low of $1.00 and a high of $7.68. The stock's 50-day moving average is $1.99, while the 200-day moving average stands at $1.94.

Analyst Ratings and Predictions

Wall Street analysts have recently shared their insights regarding Immuneering. Chardan Capital reaffirmed a "buy" rating with a price target of $13.00 in a research note earlier this month. Additionally, Needham & Company LLC also reiterated a "buy" rating, setting their price target at $12.00 in early February. However, Morgan Stanley downgraded Immuneering from an "equal weight" to an "underweight" rating in December. Overall, one analyst has rated the stock as a sell, three have given it a hold rating, and four analysts have rated it as a buy. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $12.20.

About Immuneering

Immuneering Corporation is a clinical-stage oncology company focused on developing treatments for various cancer types. Its leading product candidates include IMM-1-104, a dual-MEK inhibitor currently in Phase 1/2a clinical trials for treating patients with cancers such as pancreatic, melanoma, colorectal, and non-small cell lung cancer driven by mutations in RAS and/or RAF. Another candidate, IMM-6-415, is in the Investigational New Drug application stages aimed at treating solid tumors.

Investment Considerations

For potential investors considering whether to invest in Immuneering, it might be wise to note that while the analysts view the stock as a hold at present, there are several other stocks recommended by top-rated analysts as better investment options at this time.

Earnings, Stocks, Market